Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes | Aplastic Anemia & MDS International Foundation Return to top.
  1. Education
  2. Research Articles
  3. Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes

Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes

Journal Title: 
American Journal of Hematology
Primary Author: 
Garcia-Manero G
Author(s): 
Garcia-Manero G, Diez-Campelo M, Vellenga E, Jacoby MA, Merchan B, Breems D, Cortelezzi A, Doronin V, Gomez V, Beckers M, Della Porta MG, Varsos H, Xiu L, DeAngelis N, Nnane I, Rose E, van Eygen K
Original Publication Date: 
Friday, January 15, 2021
Full Article on PubMed: 
https://www.ncbi.nlm.nih.gov/pubmed/33448430/
Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
Share with addtoany.com.